Expression analysis of PTEN and CDKN1C/p57kip2 in cancerous tissues from Iranian patients with gastric cancer
Keywords:
Stomach Neoplasms, Gene expression, PTEN Phosphohydrolase, Cyclin-Dependent Kinase Inhibitor p57, Real-time PCRAbstract
Background: Since gastric cancer (GC) is the third prevalence cause of cancer-related death, early diagnosis can improve survival rate. Some studies indicated that loss of tumor suppressor gene (TSG) is a key event in gastric carcinoma. Based on epigenetic alteration each population is valuable to evaluate. So this study investigated the expression rate of phosphatase and tensin homolog (PTEN) and a cyclin-dependent kinase inhibitor of G1 cyclin complexes (CDKN1C) in a population in Iran. Methods: 64 gastric samples (32 tumoral gastric tissues and 32 healthy adjacent tissues) were collected from patients referred to Imam Khomeini Hospital Cancer Institute during 2008-2011. Total RNA was extracted, cDNA was synthesized, and then expression level of PTEN and CDKN1C was detected by Real time-PCR. Results: Our results displayed PTEN and CDKN1C expression significantly decreased in cancerous tissues compared to healthy adjacent tissues (P<0.05). In the case of PTEN, ΔΔCT was calculated 3.04 that showed 8.2 times expression reduction in tumorous tissues. Also, the ΔΔCT of CDKN1C was 2.6 which represents 6.1 times expression reduction in tumorous samples. Furthermore, there is an association between PTEN and CDKN1C expression and vascular invasion. However, the study of parameters such as age, tumor size, sex, ethnicity, and stage were not significantly associated with decreased expression of these TSGs. Conclusion: A significant expression reduction of both TSGs in tumoral tissues compared with healthy adjacent tissues suggest that these genes have an important role in gastric cancer incidence and future researches may reveal their advantage in treatment and diagnosis.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.